⌕
Iovance Biotherapeutics · IOVA · Nasdaq
Tenet 52 · Mixed
Compare
$7.76+1.70%At closeTenet 52 · Mixed
$7.76+0.13 (+1.70%)
At close: Nov 13, 2026, 4:00 PM ET· Nasdaq · USD

Iovance Biotherapeutics (IOVA) Stock

Iovance Biotherapeutics (IOVA) closed at $7.76 on Nov 13, 2026; its Tenet Score is 52 of 100 against 297 Healthcare peers.

Sources Company filings, market prices and computed by Tenet Filings, prices and TenetScore as of How we compute thisNot investment advice

21 figures withheld by our checks. Each blank figure names its reason.

Key stats

Previous close
$7.76
Nov 13, 2026
Market cap
$3.6B
share price × the latest quarter's diluted weighted-average share count (vendor)
52-week range
2.08 – 15.37
low → high · as of close, Nov 13, 2026
Tenet Score
52/100
Mixed · 297 Healthcare peers

Industry: Drugs

Iovance Biotherapeutics Inc scores 52/100. Mixed. Strongest on financial health, quality is the soft spot versus 297 Healthcare peers. Insufficient inputs: Tenet 52 is built from 3 of 4 pillars, from 55% of its inputs. Growth is left out because no growth rate could be measured.

Tenet Score · vs sector

n=297
52/ 100
Mixed
Fundamental composite — rates the business, not the timing.
Each metric's standing vs the company's own record is shown on the Statistics tab.
Value
51
Quality
31
Health
76
Growth
—

Factor grades

Grid rings: 25 · 50 · 75 · 100 percentile
Growth omitted — no data yet.
ValueCQualityDHealthBGrowth—MomentumA+
A grade is a label over the shown score. Value/Quality/Health/Growth are sector percentiles; Momentum ranks 12−1 return across the equity universe — a lens, never folded into the Tenet Score.
Show the math →

Price

Loading chart…
P/E
—
Not meaningful: the company made a loss.
P/B
4.4×
price to book value
P/S
9.5×
price to fiscal 2025 sales
ROE
−29%
return on equity
Operating margin
−153.1%
fiscal 2025, before interest and tax
Net margin
−58.2%
of revenue kept
Current ratio
5.20
current assets to liabilities
Net debt / EBITDA
—
Not meaningful: EBITDA is zero or negative.
EPS CAGR 5y
—
This growth figure starts in a period outside the history your plan includes.
Div yield
—
no yield on file

The whole report, at a glance · every card is a live peek, click any to open the section

About Iovance Biotherapeutics Inc

Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical s…

Composite computed Nov 13, 2026 · peer basis: Healthcare (n=297) · every glimpse links to its full section with sources · not investment advice.

ETF exposure

held by 94 US ETFs · top wrappers by weightSee all ETFs holding IOVA →

Similar-sized companies in Drugs

The 10 companies in this industry closest in market cap, as of Nov 13, 2026.

What sector and industry is Iovance Biotherapeutics in?

Iovance Biotherapeutics is in the Healthcare sector and the Drugs industry.

What is Iovance Biotherapeutics' Tenet Score?

Iovance Biotherapeutics' Tenet Score is 52 out of 100, ranked against 297 Healthcare peers as of Nov 13, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.